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Abstract  
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease which causes 
progressive and eventually fatal loss of motor function. Here we describe genetic and pathological 
characterisation of brain tissue banked from 19 ALS patients over nearly 20 years at the Department 
of Anatomy and the Centre for Brain Research, University of Auckland, New Zealand. We screened 
for mutations in SOD1, TARDBP, FUS, and C9ORF72 genes, and for neuropathology caused by 
phosphorylated TDP-43, dipeptide repeats and ubiquilin. We identified two cases with C9ORF72 
repeat expansions. Both harboured phosphorylated TDP-43 and dipeptide repeat inclusions. We show 
that dipeptide repeat inclusions can incorporate or occur independently of ubiquilin. We also 
identified one case with a UBQLN2 mutation, which showed phosphorylated TDP-43 and 
characteristic ubiquilin protein inclusions. This is the first study of ALS genetics in New Zealand, 
adding New Zealand to the growing list of countries in which C9ORF72 repeat expansion and 
UBQLN2 mutations are detected in ALS cases. 

















1. Introduction  
The Neurological Foundation of New Zealand Human Brain Bank at the Centre for Brain Research, 
University of Auckland, was established in 1994 to collect brain and associated tissue from donors 
with neurological diseases including amyotrophic lateral sclerosis (ALS). With a growing number of 
genetic causes of ALS identified by researchers internationally we sought to examine the genetics and 
neuropathology of our ALS brain bank cases as a subset of ALS patients in New Zealand. 
The genetic basis for approximately 18% of ALS cases is accounted for, with the GGGGCC 
expansion mutation in intron 1 of C9ORF72 alone comprising ~10% of all ALS. Exonic mutations in 
SOD1, FUS and TARDBP, along with rarer ALS genes (UBQLN2, OPTN, TBK1, SQSTM1 etc.) found 
predominantly in FALS cases, comprise the remaining cases (Renton, et al., 2014). Despite the 
diverse genetic and environmental factors, ~97% of all ALS cases show a common neuropathology 
characterised by the deposition of phosphorylated TDP-43 aggregates (Neumann, et al., 2006). The 
presence of additional protein aggregates can indicate specific genetic causes of ALS. For example, in 
addition to TDP-43 pathology, C9ORF72 mutations also cause dipeptide repeat (DPR) protein 
aggregates in the cerebellum and hippocampus (Ash, et al., 2013, Mori, et al., 2013). Conversely, 
FUS and SOD1 mutant cases do not show TDP-43 proteinopathy, but rather deposition of the mutant 
proteins themselves (Mackenzie, et al., 2007, Vance, et al., 2009). Neuropathological analyses can 
therefore be used in conjunction with genetics to fully characterise ALS cases. 
Here we examine genetic and pathological features of ALS in New Zealand using banked 
brain tissue. We identify C9ORF72 and UBQLN2 as genetic causes of ALS in New Zealand and 
confirm that cases with these mutations display characteristic neuropathological lesions. These 
findings will allow us to best utilise and share our existing bequests as well as establishing a platform 
for larger genetic and neuropathological studies of ALS in New Zealand.  
2. Materials and Methods 
2.1 Subjects, ethics and human tissue banking 
Brain tissue was collected from 4 controls and 19 ALS cases through the Neurological Foundation of 
NZ Human Brain Bank from 1995-2013. Clinical and neuropathological diagnoses were performed by 















NZ. Informed written consent was obtained from all donors and next of kin. Ethical approval was 
granted by the University of Auckland Human Participants Ethics Committee.  
2.2 DNA extraction from fixed and fresh brain tissue 
One hundred mg fixed-frozen tissue and/or 300 mg fresh-frozen tissue from lateral cerebellum and/or 
rostral superior frontal gyrus was used. DNA was extracted from fresh tissue (n=10 cases) using 
standard phenol-chloroform-isoamyl alcohol extraction and DNA clean-up performed using 
Microclean (Microzone). DNA was extracted from fixed-frozen tissue (n=17 cases) using the QiaAmp 
FFPE Tissue Kit (Qiagen).  
2.3 Sanger sequencing and repeat-primed PCR 
All coding exons and flanking sequence of SOD1 (Refseq NM_00454), exon 6 of TARDBP (Refseq 
NM_007375), and exons 6, 14 and 15 of FUS (Refseq NM_001170937) were amplified using 
standard PCR and directly sequenced with Big-Dye Terminator v1.1 on an ABI3130 DNA analyser 
(Applied Biosystems). Samples were screened for the C9ORF72 GGGGCC repeat expansion 
mutation using repeat-primed PCR (DeJesus-Hernandez, et al., 2011) and fragment  analysis  
conducted  on  an  ABI3130  DNA  analyser  and  peaks  visualized  using  Genemapper 4.0.  
2.4 Neuropathology 
Fifty micron free-floating sections were taken from fixed-frozen sensory-motor cortex blocks or 
hippocampus blocks and immunohistochemistry performed using antibodies listed in Supplementary 
material (Waldvogel, et al., 2008, Waldvogel, et al., 2006). Wide-field images were acquired using a 
Nikon Eclipse Ni microscope (20x magnification, 0.13 NA) and confocal images sourced using a 
Zeiss LSM 710 inverted confocal microscope (63x magnification, 1.4 NA, Z-step 0.34 µm) with ZEN 
2012 software (Carl Zeiss). Maximum intensity Z-projections and orthogonal projections were 


























Male: female (n) 50% (2):50% 
(2) 
47% (9): 53% 
(10) 
53% (9): 47% 
(8) 
0%:100% (2) 
Family history of ALS (n) - 26% (5) 18% (3) 100% (2) 
Mean age at onset  
(years ± SD, range)  
- 58.3 ± 14.9,  
32-87 
59.3 ± 15.9,  
32-87 
49.5 ± 3.5,  
47-52 
Mean age at death  
(years ± SD, range) 
64.3 ± 2.9,  
60-67 
61.7 ± 13.5,  
41-88 
62.8 ± 14.3,  
41-88 
53.0 ± 0,  
53-53 
Mean post mortem delay 
(hours ± SD, range) 
19.1 ± 6.9,  
9-23.5 
20.8 ± 17.1, 
3-69* 
*Excluding MN2 for which this information was unavailable. 
A detailed clinical description of cases harbouring mutations can be found in Supplementary Material. 
3.2 Genetic analysis of banked ALS cases 
One of our cases had tested positive for UBQLN2 p.T487I mutation in life (patient IV:18 in 
(Williams, et al., 2012)). Another case tested negative for C9ORF72, SOD1, TARDBP and FUS 
during life. All other cases were screened for these genes using DNA extracted from brain. Fresh-
frozen brain DNA, available for 10 cases, gave a high rate of sequencing success. Fixed-frozen brain 
DNA gave only ~50% viable sequence. We identified one fALS patient (MN18) with C9ORF72 
repeat expansion (Fig. 1A), however DNA was not available from other affected family members to 
test segregation. 
3.3 Neuropathology of banked ALS cases 
We next conducted immunohistochemistry on all 19 cases. All showed classical phosphorylated TDP-
43 deposits in the motor cortex (Fig. 1B), thus ruling out SOD1 and FUS gene mutations (Mackenzie, 
et al., 2007, Vance, et al., 2009). No phosphorylated TDP-43 inclusions were seen in controls, nor 
when phospho-TDP-43 primary antibody was omitted. We also screened using an antibody to the 
poly-glycine-proline DPR (Ash, et al., 2013). The C9ORF72-positive case (MN18) showed hallmark 
deposition of DPR aggregates in the dentate gyrus and cornus ammonis (CA) regions of the 
hippocampus (Fig. 1C a-d). A second fALS case (MN2) also showed DPRs. For this case, C9ORF72 















patient’s family revealed an affected offspring had tested positive. No DPR staining was seen in 
control hippocampus, any C9ORF72-negative ALS cases, nor when primary antibody was omitted. 
Finally, by screening using an antibody to ubiquilin 2 we confirmed that the case with UBQLN2 
p.T487I mutation (MN17) showed deposition of ubiquilin in the hippocampus, particularly in the 
parahippocampal region and molecular layer of the dentate gyrus but not in the granular layer (Fig. 
1D a-d). In cases with C9ORF72 mutation, ubiquilin-positive inclusions were observed in the CA 
regions and in both the granular and molecular layers (Fig. 1D e-h). Using double-label confocal 
microscopy we found that DPRs in the granular layer could be found alone, or decorating a core of 
ubiquilin (Fig. 1E). No ubiquilin staining was seen when primary antibody was omitted. 
4. Discussion  
This study is the first to explore the genetics and neuropathology of ALS in New Zealand. With a total 
population of only 4.5 million, and an estimated current cohort of 300 people living with ALS, ALS 
research in New Zealand to date has been on a small scale. However after 20 years of banking brain 
tissue, and with growing national and international support for ALS research, the time was ripe for 
characterisation of our bank as a foundation for growth of a New Zealand ALS research programme.  
Using combined genetic and neuropathological screening we identified two C9ORF72 
mutation carriers and a UBQLN2 p.T487I carrier. The C9ORF72-positive cases showed abundant 
deposition of DPRs in the hippocampus. Although TDP-43 proteinopathy correlates better with 
regional neurodegeneration (Mackenzie, et al., 2013), DPRs are pathognomonic for C9ORF72-linked 
disease thus staining for DPRs can augment genetic screening. Before the discovery of DPRs it was 
found that C9ORF72-positive cases could also be distinguished by the presence of p62 and ubiquilin 
protein pathology in the hippocampus and cerebellum (Al-Sarraj, et al., 2011, Brettschneider, et al., 
2012). Although TDP-43 inclusions can be ubiquilin-modified (Deng, et al., 2011) they are rare in 
hippocampus before late stage (Brettschneider, et al., 2013) therefore hippocampal ubiquilin 
pathology is considered a surrogate for DPRs (Brettschneider, et al., 2012, Mann, et al., 2013). We 
showed using double-label immunofluorescence that polyGP DPRs are ubiquilin-modified in the 
dentate granular layer, while ubiquilin inclusions in the molecular layer were DPR-negative. 















UBQLN2 gene mutation (Deng, et al., 2011, Williams, et al., 2012), and indeed we detected 
hippocampal ubiquilin inclusions in case MN17 with UBQLN2 p.T487I mutation.  
While this study was essential for characterising our banked tissue for future use, we screened 
only a small number of patients who may not necessarily be representative of the wider New Zealand 
ALS cohort. For instance, 5 of our 19 cases (26%) had a family history of ALS while most studies 
report that 5-10% of ALS is familial. Their over-representation in our brain bank may suggest that 
familial ALS patients are more highly motivated to bequeath tissue for research. For this reason, the 
inclusion in our cohort of a case with a rare UBQLN2 mutation should not be over interpreted. The 
frequency of C9ORF72 mutation in our cohort, 2 of 5 familial cases (40%), agrees with the expected 
frequency of 37.6% for European populations (Majounie, et al., 2012). 
This study profiles ALS genetics and pathology in a small New Zealand cohort. Moving 
forward, we seek to press for inclusion of New Zealand ALS patients in international cohort studies 
and clinical trials.   
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Figure legend 
Figure 1. Phosphorylated TDP-43, C9ORF72 dipeptide repeat, and ubiquilin pathology in New 
Zealand ALS patients. 
(A) Repeat-primed PCR showed C9ORF72 repeat expansion in MN18. (B) Phospho-TDP-43 
inclusions were seen in the motor cortex of all ALS patients. p-TDP-43 neuronal cytoplasmic 
inclusions (NCI) (a, arrow), threads (b) skeins (c) and dystrophic neurites (DN, d). Scale bars 20 µm. 















pyramidal cells of CA1-4 (a) and granule cells of the dentate gyrus (DG) (c). Pyramidal cells with 
diffuse staining with or without concomitant NCI (b), dipeptide-containing DN (d), and dot-like 
intranuclear inclusions (a, arrow) were seen occasionally. Scale bars 20 µm. (D) Ubiquilin inclusions 
were seen in the hippocampus of three ALS patients. MN17, harbouring a UBQLN2 p.T487I 
mutation, showed abundant neuritic inclusions in the molecular layer of the DG (a, enlarged in b). 
Parahippocampal gyrus (c, enlarged in d) had the highest load of neuritic inclusions and occasional 
pyramidal NCI (d, arrow head). The granular layer of the DG, devoid of inclusions in MN17, showed 
abundant NCI in C9ORF72 repeat expansion cases MN2 and MN18 (e left, enlarged in g). In these 
cases the CA regions and the molecular layer of the DG showed diffuse and aggregated neuritic 
ubiquilin and DN (e right, enlarged in f). Occasional pyramidal NCI were seen in the CA regions 
(arrow head). Scale bars 20 µm (b,d,f-h,) or 50 µm (a,c,e). (E) Colocalisation of ubiquilin and DPRs. 
In MN2 and MN18 ubiquilin inclusions were found with (a,b, arrow heads) or without (a, arrow) a 
shell of DPRs. DPRs without a ubiquilin core were also seen (a, red arrow). Main images are 
maximum intensity z-projections, panels are orthogonal projections. Scale bars 20 µm. 
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Supplementary Material  
Immunohistochemistry 
Primary antibodies: 
Phosphorylated TDP-43 (rabbit anti-phosphoserine 409/410, 1 in 50,000, #CAC-TIP-PTD-P02, 
RRID: AB_1961898, Cosmo Bio Co. Ltd., Tokyo, Japan); C9ORF72 dipeptide repeat proteins (rabbit 
anti-C9RANT, 1 in 15,000, #NBP2-25018, Novus Biologicals, Littleton, CO); Ubiquilin (mouse anti-
PLIC-2 (QR-2) Ubiquilin 2 antibody (also detects ubiquilins 1 and 4), 1 in 1000, #SC-100612, RRID: 
AB_2272422, Santa Cruz Biotechnology, Dallas, TX). Antigen retrieval (microwaving 30 s in 0.1 M 
sodium citrate buffer, pH 4.6) was performed for phosphorylated TDP-43 only, before blocking. 
Biotinylated secondary antibody (goat anti-rabbit, #B7389, RRID: AB_258613; or anti-mouse, 
#B7264, RRID: AB_258607, 1 in 1000, Sigma-Aldrich, St. Louis, MO) was applied overnight and 
ExtrAvidin peroxidase (1 in 1000, #E2886, Sigma-Aldrich) applied for 4 h at room temperature. 
Colour development with 3,3'-Diaminobenzidine (DAB) was allowed to proceed for 20 min. After de- 
and re-rehydration, sections were counterstained with cresyl violet (Nissl stain) for 15 min. For 
fluorescent immunolabelling, secondary antibodies were added overnight at room temperature (1 in 
500, Alexa Fluor® 488-conjugated goat anti-mouse, #A11029, RRID: AB_2534088; and Alexa 
Fluor® 594-conjugated goat anti-rabbit, #A11012, RRID: AB_2534079, ThermoFisher Scientific, 
Waltham MA), followed by counterstaining with Hoechst 33342 (1 µg/mL, #H3570, ThermoFisher 
Scientific) for 15 minutes at room temperature and mounted with ProLong® Gold antifade mountant 
(#P36930, ThermoFisher Scientific). 
Clinical features of C9ORF72 and UBQLN2 positive cases  
Patient MN2 
The patient was a European female presenting at age 52 with ALS of spinal onset, with wasting and 
weakness of the upper limbs progressing to quadriplegia. The patient developed a bulbar palsy and 
prior to death was severely dysphagic and almost entirely anarthric. The patient died at the age of 53. 
The patient’s grandmother was diagnosed with progressive muscular atrophy. The patient’s mother 















Pick’s disease but neither neurofibrillary tangles nor plaques were detected. The patient’s brother and 
two aunts also died of ALS.  
Patient MN18 
The patient was a European (Australian) female with onset at age 47, presenting with lower limb 
weakness. Concomitant FTD was not suspected. The patient died at the age of 53. The patient’s 
mother was diagnosed with early Alzheimer’s at age 60, and a maternal aunt was diagnosed with 
unspecified dementia. A maternal uncle was diagnosed with MND but was not known to have 
dementia.  
Patient MN17 
The patient was a European female, presenting with ALS of spinal onset at the age of 58 with distal 
upper limb weakness, progressing to severe weakness in all limbs and anarthria within 3 years. FTD 
was suspected clinically, developing fairly late, with confirmed executive dysfunction. The patient 
died at the age of 61. The patient’s mother, sister, and brother died of ALS aged 48, 38, and 43 years, 
respectively. The family history of ALS was extensive. At the time of her death, 9 of 22 of the 
patient’s family had died of ALS. No male-to-male transmission was seen, consistent with X-linked 
disease. This patient and kindred have been described in detail previously, during the patient’s life 































• Genetic and neuropathological characterisation of 19 ALS patients in New Zealand 
• C9ORF72 and UBQLN2 mutations are genetic causes of ALS in New Zealand  
• Hippocampal ubiquilin distinguishes UBQLN2, C9ORF72-negative and -positive cases  
• Hippocampal dipeptide repeat inclusions surround or occur independently of ubiquilin 
 
 
 
 
